Experimental cell therapy tested for devastating brain and nerve autoimmune disorders

This early-phase study is testing the safety and initial effectiveness of an experimental cell therapy called CNCT19 injection for people with severe, relapsing autoimmune diseases that attack the brain and nerves. It will enroll 18 adults whose conditions—like multiple sclerosis or myasthenia gravis—have not improved with standard treatments. Researchers will monitor patients closely for side effects and see if the therapy helps reduce disease activity and disability.